Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.43 USD | +1.04% | -0.57% | -9.55% |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 249 times its estimated earnings per share for the ongoing year.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.55% | 1.33B | B+ | ||
-8.41% | 8.88B | B+ | ||
-0.39% | 1.39B | D | ||
-11.11% | 1.13B | - | ||
-20.27% | 837M | - | - | |
+0.81% | 451M | - | ||
+0.90% | 427M | - | - | |
-25.71% | 329M | - | - | |
-54.07% | 328M | - | ||
-2.84% | 207M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OMI Stock
- Ratings Owens & Minor, Inc.